Table 1 Characteristics, findings, treatments, and clinical outcome of reported polyneuropathy cases
Variable | Sample size | Median (IQR) / n (%) | |
|---|---|---|---|
Guillain Barre syndrome | |||
Age (year), Median (IQR) | 171 | 58 (43, 70) | |
Gender, n (%) male | 108 (63%) | ||
mRNA-based vaccinea | 1st dose / 2nd dose / Booster | 52 | 34 (65%) / 16 (31%) / 2 (4%) |
Vector-based vaccineb | 1st dose / 2nd dose | 116 | 105 (91%) / 11 (9%) |
Clinical variant | BFP / Typical / MFS / SM / Paraparetic / FDFN | 58 | 16(28%)/12(21%)/9(16%)/9(16%)/7 (12%)/5(9%) |
Pathogenic subtype | AIDP / AMAN / AMSAN | 95 | 77 (81%) / 11(12%) / 7(7%) |
Time from vaccine to symptom (days), Median (IQR) | 171 | 13 (8, 17) | |
Tests | |||
Diagnostic MRI | 69 | 20 (29%) | |
Diagnostic EMG / NCS | 135 | 131 (97%) | |
Laboratory tests | Positive Albuminocytological dissociation | 123 | 105 (85%) |
Positive Anti ganglioside Antibodies | 70 | 17 (24%) | |
Treatment | |||
IVIG only / + PLEX / or + Corticosteroids | 142 | 107 (75%) / 10 (7%) / 7 (5%) | |
PLEX only / Corticosteroid only / Conservative | 9 (6%) / 4 (3%) / 4 (3%) | ||
Clinical outcomes | |||
Complete / Partial / or Poor recovery at follow-up / or Death | 123 | 65 (53%) / 46 (37%) / 11 (9%) / 3 (2%) | |
Parsonage-turner syndrome | |||
Age (year), Median (IQR) | 40 | 50 (38, 63) | |
Gender, n (%) male | 25(62.5%) | ||
mRNA-based vaccinea | 1st dose / 2nd dose | 28 | 14 (50%) / 14 (50%) |
Vector-based vaccineb | 1st dose / 2nd dose | 12 | 10 (83%) / 2 (17%) |
Symptom side | Injection side / Contralateral / Bilateral | 38 | 30 (79%) / 5 (13%) / 3 (%) |
Presenting symptoms | Shoulder or arm pain / Weakness / Paresthesia | 28 | 20 (71%) / 17 (61%) / 8 (29%) |
Time from vaccine to symptom (days), Median (IQR) | 40 | 8 (5, 15) | |
Tests | |||
Positive EMG / NCS | 26 | 22 (85%) | |
Positive Brachial plexus MRI | 35 | 11 (31%) | |
Treatment | |||
Corticosteroid without / with GABA analogue | 38 | 14 (37%) / 10 (26%) | |
NSAID + GABA analogue | 2 (5%) | ||
IVIG | 1 (2.5%) | ||
Clinical outcomes | |||
Complete / Partial / or Poor recovery at follow-up | 37 | 15 (41%) / 15 (41%) / 7 (18%) | |
Facial nerve palsy | |||
Age (year), Median (IQR) | 19 | 38 (34, 57) | |
Gender, n (%) male | 8 (42%) | ||
Prior history of facial nerve palsy | 4 (21%) | ||
mRNA-based vaccinea | 1st dose / 2nd dose | 14 | 11 (79%) / 3 (21%) |
Vector-based vaccineb | 1st dose / 2nd dose | 5 | 4 (80%) / 1 (20%) |
Presenting symptoms | Ipsilateral / Bilateral facial weakness | 19 | 17 (90%) / 2 (10%) |
Time from vaccine to symptom (days), Median (IQR) | 19 | 3 (2, 6) | |
Treatment | |||
Corticosteroids only/ + viral agents / + Fluorometholone / or + topical antibiotics | 18 | 10 (56%) / 6 (33%) / 1 (6.5%) / 1 (6.5%) | |
Clinical outcomes | |||
Complete recovery | 17 | 17 (100%) | |
Small fiber neuropathy | |||
Age (year), Median (IQR) | 5 | 52 (36, 60.5) | |
Gender, n (%) male | 0 | ||
mRNA-based vaccinea | 1st dose / 2nd dose / Booster | 0 / 4 (80%)/ 1 (20%) | |
Time from vaccine to symptom (days), Median (IQR) | 10 (4, 19) | ||
Presenting symptoms | Weakness/gait disturbances/dysesthesia/paresthesia/dysphagia | 2(40%)/2(40%)/2(40%)/1(20%)/1(20%) | |
Tests | Diagnostic skin Punch biopsy | 4 | 4 (100%) |
Treatment | Symptom treatment / corticosteroid + IVIG | 4 | 3 (75%)/ 1 (25%) |
Outcome | Resolved in less than two weeks | 3 | 3 (100%) |